...Diego, Calif.) hired Chris Mathes as chief commercial officer. He was chief commercial officer at Icagen...

...and Bayer partnered for up to two years to develop new X-ray fluorescence assays using Icagen’s...
...companies declined to disclose financial terms. XRpro allows for the high throughput assessment of transporters. Icagen...
...Research Triangle Park, N.C. Bayer AG (Xetra:BAYN), Leverkusen, Germany Business: High throughput screening Nora Weintraub Bayer AG Icagen...

...obtained in its 2011 acquisition of Icagen Inc. The purchase includes Pfizer’s rights to the “Icagen”...
...Inc. The purchase includes Pfizer’s rights to the “Icagen” name and trademark. XRpro relaunched as Icagen...
...services. Pfizer scientists associated with the ion channel biology platform will transition to the new Icagen...

...of new channel isoforms is a goal, as is developing the company's drug screening capabilities. ICAgen...

...an ion channel thought to be specifically expressed in the atrial tissue of the heart. ICAgen...
...funding for two years, milestones, and royalties. The deal could be worth $75 million to ICAgen...
...Bristol-Myers will receive exclusive worldwide rights to lead compounds for the treatment of atrial fibrillation. ICAgen...

...CFO, a newly created position, formerly EVP of finance and corporate development and CFO of Icagen...

...Pfizer completed its acquisition of Icagen, which will become a wholly-owned subsidiary of Pfizer. Icagen will...
...unit for pain, sensory disorders and regenerative medicine (see BioCentury, July 25 & Sept. 26). Icagen...

...Pfizer completed its subsequent tender offer to acquire the remaining shares of Icagen, acquiring 5.4 million...
...in a second-step merger, which is subject to Icagen shareholder approval (see BioCentury, Sept. 19). Icagen...

...Pfizer extended for the final time its subsequent tender offer for the remaining shares of Icagen...
...completed its initial tender offer for Icagen, acquiring 4.6 million shares (see BioCentury, Sept. 12). Icagen...